Johnson & Johnson (JNJ) 100.30 $JNJ
United States Surgical Appliance and Supplies Manufacturing Industry and its International Trade [2014 Edition]
M2 - 54 mins ago
Research and Markets (http://www.researchandmarkets.com/research/bpjwbd/surgical) has announced the addition of Supplier Relations US, LLC's new report "Surgical Appliance and Supplies Manufacturing Industry in the U.S. and its International Trade [2014 Edition]" to their offering. This U.S. industry comprises establishments primarily engaged in manufacturing surgical appliances and supplies. Examples of products made by these establishments are orthopedic devices, prosthetic appliances, surgical dressings, crutches, surgical sutures, and personal industrial safety devices (except protective eyewear). This 2014 publication of Surgical Appliance and Supplies Manufacturing Industry report is the comprehensive market research guide for the industry. It contains the latest information on the industry's key financial data, competitive landscape, cost and pricing, and trends during the current environment, including the output and shipment changes over the past months. In this report, you will find industry data on the following major categories: - Executive Summary - Industry Income Statement - Industry Balance Sheet - Capital Expenditure - Industry Cost Analysis - Industry Pricing Analysis - Industry Foreign Trade - Industry Structure - Competitive Landscape Companies Mentioned - Baxter International Inc. - Becton, Dickinson & Company - Boston Scientific Corporation - Cardinal Health, Inc. - Cooper Companies Inc. - Covidien - Edwards Lifesciences Corporation - Hill-Rom - Intuitive Surgical, Inc. - Invacare Corporation - Johnson & Johnson - Kimberly-Clark Corporation - Kinetic Concepts, Inc. - Medtronic, Inc. - Mine Safety Appliances Company - Pall Corporation - Royal Philips Electronics - St. Jude Medical, Inc. - STERIS Corporation - Stryker Corporation - Synthes North America - Teleflex Incorporated - West Pharmaceutical Services, Inc. - Wright Medical Group, Inc. - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/bpjwbd/surgical
Major Depressive Disorder - Pipeline Review, H1 2014: Includes 30 Company Profiles
M2 - 1 hr 16 mins ago
Research and Markets (http://www.researchandmarkets.com/research/8lbldl/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alkermes - Angelini Group - Aniona - AstraZeneca - BRAINco Biopharma - Bionure - BrainCells Inc. - Cerecor Inc. - Dainippon Sumitomo Pharma - Dart NeuroScience - Edgemont Pharmaceuticals - Eli Lilly and Company - Euthymics Bioscience - F. Hoffmann-La Roche - Fabre-Kramer Pharmaceuticals - H. Lundbeck - Intas Pharmaceuticals - Johnson & Johnson - Luye Pharma Group - M's Science Corporation - Methylation Sciences - Naurex - NeurOp Corporation - Neuralstem - Neurocrine Biosciences - OPKO Health - Otsuka Holdings - PharmaNeuroBoost - Reviva Pharmaceuticals - Richter Gedeon - Sunovion Pharmaceuticals - Suven Life Sciences - Taisho Pharmaceutical Co., Ltd. - e-Therapeutics plc - nLife Therapeutics, S.L. For more information visit http://www.researchandmarkets.com/research/8l...depressive
Final Glance: Medical Devices companies
AP - Wed May 28, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Wed May 28, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
AbbVie Up on HCV Filing in Canada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 28, 2:04PM CDT
AbbVie Inc. (ABBV) filed new drug submission (NDS) to Health Canada for its investigational hepatitis C virus (HCV) infection therapy.
EU Nod for Eli Lilly/Boehringer's Jardiance (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 28, 1:26PM CDT
Eli Lilly and Company (LLY) and partner Boehringer Ingelheim announced that the European Commission (EC) has approved their sodium glucose co-transporter-2 (SGLT2) inhibitor, Jardiance
Midday Glance: Pharmaceuticals companies
AP - Wed May 28, 12:19PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Wed May 28, 12:19PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
DePuy ASR Lawsuit News: Trial of Australian Class Action Lawsuit Postponed Until Next Year, Bernstein Liebhard LLP Reports
PR Newswire - Wed May 28, 10:49AM CDT
Australia's first trial of a DePuy ASR lawsuit (http://www.consumerinjurylawyers.com/DePuy/) has been postponed until next year, Bernstein Liebhard LLP reports. According to ABC Australia, the class action lawsuit was set to head to trial this week, but lawyers for thousands of plaintiffs who were allegedly harmed by the metal-on-metal hip sought the postponement so that they can evaluate volumes of recently-obtained evidence. Among other things, the lawsuit alleges that Johnson & Johnson and DePuy Orthopaedics knew in 2006 that the ASR was subject to a higher rate of early failure than other all-metal hips. Plaintiffs further allege that the companies had enough information to act by 2007, but did not issue the DePuy ASR recall until 2010.
Surveyed Oncologists Indicate Delayed Disease Progression is Among One of the Greatest Unmet Needs in First-Line Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer
PR Newswire - Wed May 28, 10:00AM CDT
Decision Resources Group finds that, in addition to an improvement in median overall survival (MOS), delayed disease progression is one of the greatest unmet needs in the first-line treatment of chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC). In this patient population, MOS and disease progression are also key factors that shape surveyed U.S. and European oncologists' treatment decisions. Interviewed experts consider Bayer HealthCare/Algeta's Xofigo (radium-223), a bone-seeking alpha-emitting radiopharmaceutical, to be a valuable addition to the mCRPC armamentarium and are impressed by its effect on pain relief and improving quality of life. Based on early-phase clinical data and the opinions of thought leaders interviews, late-phase emerging therapies profiled in this report are not expected to offer a significant benefit in efficacy, safety and tolerability over currently available hormonal therapies - Johnson & Johnson/Janssen Biotech/Janssen-Cilag's Zytiga (abiraterone) and Medivation/Astellas Pharma's Xtandi (enzalutamide). However, interviewed thought leaders expect that rilimogene galvacirepvec (prostvac-VF-TRICOM), an off-the-shelf therapeutic vaccine, will offer comparable efficacy, safety and tolerability over the 2013-sales-leading agent in this patient population, Dendreon's Provenge (sipuleucel-T).
Early Glance: Medical Devices companies
AP - Wed May 28, 9:37AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Early Glance: Pharmaceuticals companies
AP - Wed May 28, 9:37AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Decision Diagnostics Corp. Subsidiary Pharma Tech Enters International Markets With Conformite Europeenne (CE) Mark Submission
Marketwire - Wed May 28, 8:21AM CDT
Decision Diagnostics Corp. (OTCQB: DECN), the manufacturer of the popular GenStrip(TM), the unique Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, announced today that they have engaged a European agent to complete its submission of Conformite Europeenne (CE) Mark Technical File in order to obtain the EU market approval for the European version of its GenStrip(TM) 50 which will be marketed in Europe as the ValuPlus(TM) glucose sensor. CE Marking implies a medical device's compliance with European Union (EU) legislation and directives with respect to safety, health, environmental and consumer protection.
Coke and Pepsi Remove BVO; Prove the Power of Protests
Brandy Betz, The Motley Fool - Motley Fool - Wed May 28, 6:38AM CDT
The Coca-Cola Company and PepsiCo, Inc recently announced plans to remove a controversial additive from all of their beverages. Regardless of what the official statements say, the companies made this move due to consumer outrage started with an...
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review 2014
M2 - Wed May 28, 5:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hgsknm/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Johnson & Johnson - Boehringer Ingelheim GmbH - Amgen Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Genentech, Inc. - Isis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Oxford BioMedica plc - Plexxikon Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astex Pharmaceuticals, Inc. - Santaris Pharma A/S - A. Menarini Industrie Farmaceutiche Riunite Srl - Bayer AG - Harbor Therapeutics, Inc. - Celldex Therapeutics, Inc. - Oncogenex Pharmaceuticals, Inc. - AnGes MG, Inc. - e-Therapeutics plc - Hybrigenics S.A. - Fujifilm Corporation - CureVac GmbH - Tokai Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - Adamis Pharmaceuticals Corporation - CureTech Ltd. - Viamet Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/hgsknm/hormone
Pharmaceutical Preparation Manufacturing Industry in the U.S. and its International Trade 2014 Edition (Updated)
M2 - Wed May 28, 2:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3bnrl3/pharmaceutical) has announced the addition of Supplier Relations US, LLC's new report "Pharmaceutical Preparation Manufacturing Industry in the U.S. and its International Trade 2014 Edition" to their offering. This 2014 publication of Pharmaceutical Preparation Manufacturing Industry report is the comprehensive market research guide for the industry. It contains the latest information on the industry's key financial data, competitive landscape, cost and pricing, and trends during the current environment, including the output and shipment changes over the past months. The industry's revenue for the year 2012 was reported at $148.9 billion USD, with an estimated gross profit of 67.29%. Import was valued at $51.1 billion USD from 80 countries. The industry also exported $30.6 billion USD worth of merchandise to 198 countries. Adding import value to and subtracting export value from the industry's shipment value, the total domestic demand for the industry in 2012 was $169.4 billion USD. At 174 pages with over 150 charts and tables, the report covers topics such as current macroeconomic trends, granular product data, global trade, channel mix, government demand, and labor structure. It uses over a decade of historical data to forecast industry trends through 2017 on the domestic market, global market and overseas growth opportunities. In this report, you will find industry data on the following major categories: - Executive Summary - Industry Income Statement - Industry Balance Sheet - Capital Expenditure - Industry Cost Analysis - Industry Pricing Analysis - Industry Foreign Trade - Industry Structure - Competitive Landscape Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Bausch & Lomb Incorporated - Baxter International Inc. - Bristol-Myers Squibb Company - Cargill, Incorporated - Chattem, Inc. - Eli Lilly and Company - Endo Pharmaceuticals Holdings Inc. - Genzyme Corporation - Hospira, Inc. - Johnson & Johnson - Merck & Co. Inc. - Mylan Laboratories, Inc. - NBTY, Inc. - Pfizer Inc. - Sigma-Aldrich Corporation - Teva Pharmaceuticals USA, Inc. - The Perrigo Company - The Procter & Gamble Company For more information visit http://www.researchandmarkets.com/research/3b...maceutical Source: Supplier Relations US, LLC
Biotech Tweet of the Week: The Best of ASCO Is Yet to Come
Brian Orelli and David Williamson, The Motley Fool - Motley Fool - Tue May 27, 1:30PM CDT
On this week's episode of Biotech Banter , senior biotech specialist Brian Orelli and health-care analyst David Williamson discuss the tweet of the week from David Miller of AlpineBioVentures, who says, "Tip for those new to the ASCO thing:...
Johnson & Johnson Focusing on Quality Over Quantity
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue May 27, 1:30PM CDT
On May 22, Johnson & Johnson hosted an all-day analyst day for its medical device business. This meeting didn't really offer any major surprises, but did highlight management's intention to run this business with a focus on returns and scale...
EU Nod for Eli Lilly/Boehringer's Jardiance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 27, 10:50AM CDT
Eli Lilly and Company (LLY) and partner Boehringer Ingelheim's Jardiance (empagliflozin) is approved by the FDA for type II diabetes.
U.S. Vascular Device Market Report 2014 - Executive Summary
M2 - Tue May 27, 9:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9vlp3v/u_s_vascular) has announced the addition of the "U.S. Vascular Device Market 2014 (Executive Summary)" report to their offering. The U.S. Vascular Access Market was valued at $3.7 billion in 2013 and is expected to grow to over $5 billion by 2020 This growth is fueled by government safety and reimbursement policies created to reduce infection and injury rates. As a result, hospitals are taking steps to reduce injuries by increasing the use of safety products such as pivoting needles, shield safety products retractable syringes and catheter securement technologies. The rise in demand for vascular access devices is proportional to the addressable patient population including oncology, ICU and diabetic patients. In 2013, approximately 90% of patients who were hospitalized in the U.S. received some sort of vascular access treatment during their stay, including the use of IV catheters and syringes. One of the strongest segments driving the vascular access market is the catheter securement market, which is expected to experience double digit growth by 2020. This segment includes Ultrasound and Tip-Location technologies, Peripheral Intravenous Catheters, Dialysis Catheters and Central Venous Catheters (CVCs). Leading the market for vascular access market is Becton Dickinson (BD), despite participating in only two market segments, the PIVC and syringe & needle markets. Other major competitors in the U.S. market includes C.R. Bard, Covidien, Teleflex Medical, Johnson & Johnson and Smith & Nephew. This report includes the latest data, market analyses and competitor profiles. This market segment includes the implantable port, port needle, central venous catheter, peripherally inserted central catheter, peripheral intravenous catheter, dialysis catheter, ultrasound vascular access device and accessories, catheter securement device, syringe and needle market. Key Topics Covered: - U.S. Vascular Access Device Market - Implantable Port Market - Central Venous Catheter Market - Peripherally Inserted Central Catheter Market - Peripheral Intravenous Catheter Market - Dialysis Catheter Market - Ultrasound Vascular Access Device And Accessories Market - Catheter Securement Device Market - Syringe And Needle Market - Competitive Analysis Companies Mentioned - AngioDynamics - B. Braun - Becton Dickinson - C. R. Bard - Covidien - GE Healthcare - Medcomp - Smiths Medical - SonoSite - Teleflex Medical - Terumo Medical For more information visit http://www.researchandmarkets.com/research/9v...s_vascular
United States Surgical Appliance and Supplies Manufacturing Industry and its International Trade [2014 Edition]
M2 - 54 mins ago
Research and Markets (http://www.researchandmarkets.com/research/bpjwbd/surgical) has announced the addition of Supplier Relations US, LLC's new report "Surgical Appliance and Supplies Manufacturing Industry in the U.S. and its International Trade [2014 Edition]" to their offering. This U.S. industry comprises establishments primarily engaged in manufacturing surgical appliances and supplies. Examples of products made by these establishments are orthopedic devices, prosthetic appliances, surgical dressings, crutches, surgical sutures, and personal industrial safety devices (except protective eyewear). This 2014 publication of Surgical Appliance and Supplies Manufacturing Industry report is the comprehensive market research guide for the industry. It contains the latest information on the industry's key financial data, competitive landscape, cost and pricing, and trends during the current environment, including the output and shipment changes over the past months. In this report, you will find industry data on the following major categories: - Executive Summary - Industry Income Statement - Industry Balance Sheet - Capital Expenditure - Industry Cost Analysis - Industry Pricing Analysis - Industry Foreign Trade - Industry Structure - Competitive Landscape Companies Mentioned - Baxter International Inc. - Becton, Dickinson & Company - Boston Scientific Corporation - Cardinal Health, Inc. - Cooper Companies Inc. - Covidien - Edwards Lifesciences Corporation - Hill-Rom - Intuitive Surgical, Inc. - Invacare Corporation - Johnson & Johnson - Kimberly-Clark Corporation - Kinetic Concepts, Inc. - Medtronic, Inc. - Mine Safety Appliances Company - Pall Corporation - Royal Philips Electronics - St. Jude Medical, Inc. - STERIS Corporation - Stryker Corporation - Synthes North America - Teleflex Incorporated - West Pharmaceutical Services, Inc. - Wright Medical Group, Inc. - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/bpjwbd/surgical
Major Depressive Disorder - Pipeline Review, H1 2014: Includes 30 Company Profiles
M2 - 1 hr 16 mins ago
Research and Markets (http://www.researchandmarkets.com/research/8lbldl/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alkermes - Angelini Group - Aniona - AstraZeneca - BRAINco Biopharma - Bionure - BrainCells Inc. - Cerecor Inc. - Dainippon Sumitomo Pharma - Dart NeuroScience - Edgemont Pharmaceuticals - Eli Lilly and Company - Euthymics Bioscience - F. Hoffmann-La Roche - Fabre-Kramer Pharmaceuticals - H. Lundbeck - Intas Pharmaceuticals - Johnson & Johnson - Luye Pharma Group - M's Science Corporation - Methylation Sciences - Naurex - NeurOp Corporation - Neuralstem - Neurocrine Biosciences - OPKO Health - Otsuka Holdings - PharmaNeuroBoost - Reviva Pharmaceuticals - Richter Gedeon - Sunovion Pharmaceuticals - Suven Life Sciences - Taisho Pharmaceutical Co., Ltd. - e-Therapeutics plc - nLife Therapeutics, S.L. For more information visit http://www.researchandmarkets.com/research/8l...depressive
Final Glance: Medical Devices companies
AP - Wed May 28, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Wed May 28, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
AbbVie Up on HCV Filing in Canada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 28, 2:04PM CDT
AbbVie Inc. (ABBV) filed new drug submission (NDS) to Health Canada for its investigational hepatitis C virus (HCV) infection therapy.
EU Nod for Eli Lilly/Boehringer's Jardiance (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 28, 1:26PM CDT
Eli Lilly and Company (LLY) and partner Boehringer Ingelheim announced that the European Commission (EC) has approved their sodium glucose co-transporter-2 (SGLT2) inhibitor, Jardiance
Midday Glance: Pharmaceuticals companies
AP - Wed May 28, 12:19PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Wed May 28, 12:19PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
DePuy ASR Lawsuit News: Trial of Australian Class Action Lawsuit Postponed Until Next Year, Bernstein Liebhard LLP Reports
PR Newswire - Wed May 28, 10:49AM CDT
Australia's first trial of a DePuy ASR lawsuit (http://www.consumerinjurylawyers.com/DePuy/) has been postponed until next year, Bernstein Liebhard LLP reports. According to ABC Australia, the class action lawsuit was set to head to trial this week, but lawyers for thousands of plaintiffs who were allegedly harmed by the metal-on-metal hip sought the postponement so that they can evaluate volumes of recently-obtained evidence. Among other things, the lawsuit alleges that Johnson & Johnson and DePuy Orthopaedics knew in 2006 that the ASR was subject to a higher rate of early failure than other all-metal hips. Plaintiffs further allege that the companies had enough information to act by 2007, but did not issue the DePuy ASR recall until 2010.
Surveyed Oncologists Indicate Delayed Disease Progression is Among One of the Greatest Unmet Needs in First-Line Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer
PR Newswire - Wed May 28, 10:00AM CDT
Decision Resources Group finds that, in addition to an improvement in median overall survival (MOS), delayed disease progression is one of the greatest unmet needs in the first-line treatment of chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC). In this patient population, MOS and disease progression are also key factors that shape surveyed U.S. and European oncologists' treatment decisions. Interviewed experts consider Bayer HealthCare/Algeta's Xofigo (radium-223), a bone-seeking alpha-emitting radiopharmaceutical, to be a valuable addition to the mCRPC armamentarium and are impressed by its effect on pain relief and improving quality of life. Based on early-phase clinical data and the opinions of thought leaders interviews, late-phase emerging therapies profiled in this report are not expected to offer a significant benefit in efficacy, safety and tolerability over currently available hormonal therapies - Johnson & Johnson/Janssen Biotech/Janssen-Cilag's Zytiga (abiraterone) and Medivation/Astellas Pharma's Xtandi (enzalutamide). However, interviewed thought leaders expect that rilimogene galvacirepvec (prostvac-VF-TRICOM), an off-the-shelf therapeutic vaccine, will offer comparable efficacy, safety and tolerability over the 2013-sales-leading agent in this patient population, Dendreon's Provenge (sipuleucel-T).
Early Glance: Medical Devices companies
AP - Wed May 28, 9:37AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Early Glance: Pharmaceuticals companies
AP - Wed May 28, 9:37AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Decision Diagnostics Corp. Subsidiary Pharma Tech Enters International Markets With Conformite Europeenne (CE) Mark Submission
Marketwire - Wed May 28, 8:21AM CDT
Decision Diagnostics Corp. (OTCQB: DECN), the manufacturer of the popular GenStrip(TM), the unique Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, announced today that they have engaged a European agent to complete its submission of Conformite Europeenne (CE) Mark Technical File in order to obtain the EU market approval for the European version of its GenStrip(TM) 50 which will be marketed in Europe as the ValuPlus(TM) glucose sensor. CE Marking implies a medical device's compliance with European Union (EU) legislation and directives with respect to safety, health, environmental and consumer protection.
Coke and Pepsi Remove BVO; Prove the Power of Protests
Brandy Betz, The Motley Fool - Motley Fool - Wed May 28, 6:38AM CDT
The Coca-Cola Company and PepsiCo, Inc recently announced plans to remove a controversial additive from all of their beverages. Regardless of what the official statements say, the companies made this move due to consumer outrage started with an...
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review 2014
M2 - Wed May 28, 5:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hgsknm/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Johnson & Johnson - Boehringer Ingelheim GmbH - Amgen Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Genentech, Inc. - Isis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Oxford BioMedica plc - Plexxikon Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astex Pharmaceuticals, Inc. - Santaris Pharma A/S - A. Menarini Industrie Farmaceutiche Riunite Srl - Bayer AG - Harbor Therapeutics, Inc. - Celldex Therapeutics, Inc. - Oncogenex Pharmaceuticals, Inc. - AnGes MG, Inc. - e-Therapeutics plc - Hybrigenics S.A. - Fujifilm Corporation - CureVac GmbH - Tokai Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - Adamis Pharmaceuticals Corporation - CureTech Ltd. - Viamet Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/hgsknm/hormone
Pharmaceutical Preparation Manufacturing Industry in the U.S. and its International Trade 2014 Edition (Updated)
M2 - Wed May 28, 2:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3bnrl3/pharmaceutical) has announced the addition of Supplier Relations US, LLC's new report "Pharmaceutical Preparation Manufacturing Industry in the U.S. and its International Trade 2014 Edition" to their offering. This 2014 publication of Pharmaceutical Preparation Manufacturing Industry report is the comprehensive market research guide for the industry. It contains the latest information on the industry's key financial data, competitive landscape, cost and pricing, and trends during the current environment, including the output and shipment changes over the past months. The industry's revenue for the year 2012 was reported at $148.9 billion USD, with an estimated gross profit of 67.29%. Import was valued at $51.1 billion USD from 80 countries. The industry also exported $30.6 billion USD worth of merchandise to 198 countries. Adding import value to and subtracting export value from the industry's shipment value, the total domestic demand for the industry in 2012 was $169.4 billion USD. At 174 pages with over 150 charts and tables, the report covers topics such as current macroeconomic trends, granular product data, global trade, channel mix, government demand, and labor structure. It uses over a decade of historical data to forecast industry trends through 2017 on the domestic market, global market and overseas growth opportunities. In this report, you will find industry data on the following major categories: - Executive Summary - Industry Income Statement - Industry Balance Sheet - Capital Expenditure - Industry Cost Analysis - Industry Pricing Analysis - Industry Foreign Trade - Industry Structure - Competitive Landscape Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Bausch & Lomb Incorporated - Baxter International Inc. - Bristol-Myers Squibb Company - Cargill, Incorporated - Chattem, Inc. - Eli Lilly and Company - Endo Pharmaceuticals Holdings Inc. - Genzyme Corporation - Hospira, Inc. - Johnson & Johnson - Merck & Co. Inc. - Mylan Laboratories, Inc. - NBTY, Inc. - Pfizer Inc. - Sigma-Aldrich Corporation - Teva Pharmaceuticals USA, Inc. - The Perrigo Company - The Procter & Gamble Company For more information visit http://www.researchandmarkets.com/research/3b...maceutical Source: Supplier Relations US, LLC
Biotech Tweet of the Week: The Best of ASCO Is Yet to Come
Brian Orelli and David Williamson, The Motley Fool - Motley Fool - Tue May 27, 1:30PM CDT
On this week's episode of Biotech Banter , senior biotech specialist Brian Orelli and health-care analyst David Williamson discuss the tweet of the week from David Miller of AlpineBioVentures, who says, "Tip for those new to the ASCO thing:...
Johnson & Johnson Focusing on Quality Over Quantity
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue May 27, 1:30PM CDT
On May 22, Johnson & Johnson hosted an all-day analyst day for its medical device business. This meeting didn't really offer any major surprises, but did highlight management's intention to run this business with a focus on returns and scale...
EU Nod for Eli Lilly/Boehringer's Jardiance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 27, 10:50AM CDT
Eli Lilly and Company (LLY) and partner Boehringer Ingelheim's Jardiance (empagliflozin) is approved by the FDA for type II diabetes.
U.S. Vascular Device Market Report 2014 - Executive Summary
M2 - Tue May 27, 9:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9vlp3v/u_s_vascular) has announced the addition of the "U.S. Vascular Device Market 2014 (Executive Summary)" report to their offering. The U.S. Vascular Access Market was valued at $3.7 billion in 2013 and is expected to grow to over $5 billion by 2020 This growth is fueled by government safety and reimbursement policies created to reduce infection and injury rates. As a result, hospitals are taking steps to reduce injuries by increasing the use of safety products such as pivoting needles, shield safety products retractable syringes and catheter securement technologies. The rise in demand for vascular access devices is proportional to the addressable patient population including oncology, ICU and diabetic patients. In 2013, approximately 90% of patients who were hospitalized in the U.S. received some sort of vascular access treatment during their stay, including the use of IV catheters and syringes. One of the strongest segments driving the vascular access market is the catheter securement market, which is expected to experience double digit growth by 2020. This segment includes Ultrasound and Tip-Location technologies, Peripheral Intravenous Catheters, Dialysis Catheters and Central Venous Catheters (CVCs). Leading the market for vascular access market is Becton Dickinson (BD), despite participating in only two market segments, the PIVC and syringe & needle markets. Other major competitors in the U.S. market includes C.R. Bard, Covidien, Teleflex Medical, Johnson & Johnson and Smith & Nephew. This report includes the latest data, market analyses and competitor profiles. This market segment includes the implantable port, port needle, central venous catheter, peripherally inserted central catheter, peripheral intravenous catheter, dialysis catheter, ultrasound vascular access device and accessories, catheter securement device, syringe and needle market. Key Topics Covered: - U.S. Vascular Access Device Market - Implantable Port Market - Central Venous Catheter Market - Peripherally Inserted Central Catheter Market - Peripheral Intravenous Catheter Market - Dialysis Catheter Market - Ultrasound Vascular Access Device And Accessories Market - Catheter Securement Device Market - Syringe And Needle Market - Competitive Analysis Companies Mentioned - AngioDynamics - B. Braun - Becton Dickinson - C. R. Bard - Covidien - GE Healthcare - Medcomp - Smiths Medical - SonoSite - Teleflex Medical - Terumo Medical For more information visit http://www.researchandmarkets.com/research/9v...s_vascular
